KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (Diluted Average) (2020 - 2025)

Ionis Pharmaceuticals (IONS) has 11 years of Shares Outstanding (Diluted Average) data on record, last reported at $159.2 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 8.53% year-over-year to $159.2 million; the TTM value through Sep 2025 reached $159.2 million, up 8.53%, while the annual FY2024 figure was $149.5 million, 4.42% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $159.2 million in Q3 2025 per IONS's latest filing, down from $182.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $182.3 million in Q2 2025 and bottomed at $140.8 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $146.9 million, with a median of $143.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 0.58% in 2022, then increased 24.92% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $141.0 million in 2021, then grew by 0.59% to $141.8 million in 2022, then grew by 0.95% to $143.2 million in 2023, then increased by 4.42% to $149.5 million in 2024, then rose by 6.49% to $159.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $159.2 million in Q3 2025, $182.3 million in Q2 2025, and $158.7 million in Q1 2025.